KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConstruction in ProgressCurrent AssetsCurrent LeasesCurrent TaxesGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityNotes PayablesOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

BeOne Medicines (ONC) Accumulated Expenses: 2015-2024

Historic Accumulated Expenses for BeOne Medicines (ONC) over the last 10 years, with Dec 2024 value amounting to $803.7 million.

  • BeOne Medicines' Accumulated Expenses rose 39.63% to $1.0 billion in Q3 2025 from the same period last year, while for Sep 2025 it was $1.0 billion, marking a year-over-year increase of 39.63%. This contributed to the annual value of $803.7 million for FY2024, which is 15.85% up from last year.
  • According to the latest figures from FY2024, BeOne Medicines' Accumulated Expenses is $803.7 million, which was up 15.85% from $693.7 million recorded in FY2023.
  • BeOne Medicines' 5-year Accumulated Expenses high stood at $803.7 million for FY2024, and its period low was $346.1 million during FY2020.
  • Moreover, its 3-year median value for Accumulated Expenses was $693.7 million (2023), whereas its average is $705.6 million.
  • Data for BeOne Medicines' Accumulated Expenses shows a peak YoY spiked of 111.64% (in 2020) over the last 5 years.
  • Over the past 5 years, BeOne Medicines' Accumulated Expenses (Yearly) stood at $346.1 million in 2020, then spiked by 61.22% to $558.1 million in 2021, then increased by 11.01% to $619.5 million in 2022, then climbed by 11.99% to $693.7 million in 2023, then climbed by 15.85% to $803.7 million in 2024.